Arvinas Shares Jump 13% on FDA Approval

Arvinas shares surged up to 13% after FDA approved its breast cancer drug Veppanu (vepdegestrant).
Veppanu targets estrogen‑receptor positive, HER2‑negative, ESR1‑mutated advanced/metastatic breast cancer post‑endocrine therapy failure.
The approval marks the first FDA‑cleared PROTAC therapy, granted ahead of the June 5, 2026 PDUFA deadline.
Pfizer Inc. is mentioned as a partner in the statement on the drug’s approval.